- Home
- WGRX vs CALC Comparison
WGRX vs CALC Comparison
Compare WGRX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- CALC
- Stock Information
- Founded
- WGRX 2022
- CALC 2011
- Country
- WGRX United States
- CALC United States
- Employees
- WGRX N/A
- CALC N/A
- Industry
- WGRX Other Pharmaceuticals
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- WGRX Health Care
- CALC Health Care
- Exchange
- WGRX Nasdaq
- CALC Nasdaq
- Market Cap
- WGRX 54.8M
- CALC 44.2M
- IPO Year
- WGRX 2025
- CALC N/A
- Fundamental
- Price
- WGRX $0.58
- CALC $3.15
- Analyst Decision
- WGRX
- CALC Strong Buy
- Analyst Count
- WGRX 0
- CALC 2
- Target Price
- WGRX N/A
- CALC $14.50
- AVG Volume (30 Days)
- WGRX 1.2M
- CALC 52.6K
- Earning Date
- WGRX 11-11-2025
- CALC 11-12-2025
- Dividend Yield
- WGRX N/A
- CALC N/A
- EPS Growth
- WGRX N/A
- CALC N/A
- EPS
- WGRX N/A
- CALC N/A
- Revenue
- WGRX $36,738,599.00
- CALC N/A
- Revenue This Year
- WGRX N/A
- CALC N/A
- Revenue Next Year
- WGRX N/A
- CALC N/A
- P/E Ratio
- WGRX N/A
- CALC N/A
- Revenue Growth
- WGRX 82384.51
- CALC N/A
- 52 Week Low
- WGRX $0.56
- CALC $1.42
- 52 Week High
- WGRX $7.04
- CALC $5.65
- Technical
- Relative Strength Index (RSI)
- WGRX 28.88
- CALC 50.45
- Support Level
- WGRX $0.57
- CALC $3.15
- Resistance Level
- WGRX $0.67
- CALC $3.65
- Average True Range (ATR)
- WGRX 0.10
- CALC 0.20
- MACD
- WGRX -0.03
- CALC -0.00
- Stochastic Oscillator
- WGRX 2.56
- CALC 29.41
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.